September is Blood Cancer Awareness Month.
In conjunction with this observance, Healio highlights important research or treatment related to leukemia, lymphoma, multiple myeloma and myeloproliferative neoplasms.
- Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines.
- Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19.
- Eprenetapopt with azacitidine exhibited encouraging activity as posttransplant maintenance therapy for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
- The FDA approved zanubrutinib for adults with Waldenström macroglobulinemia.
- A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer.
- Pembrolizumab (Keytruda, Merck) plus gemcitabine, vinorelbine and liposomal doxorubicin demonstrated substantial efficacy as second-line therapy among patients with relapsed or refractory classical Hodgkin lymphoma.
- Teclistamab (JNJ-64007957, Janssen) showed encouraging efficacy among patients with relapsed or refractory multiple myeloma.
- Healio spoke with hematologist-oncologists and transplant physicians about improved outcomes with hematopoietic stem cell transplantation, decreases in HSCT complications based on advances in supportive care and conditioning regimens, promising treatments for graft-versus-host disease, and how greater access to transplantation is now potentially providing a curative option for older and frailer populations.
- Healio explored how oncologists, geneticists and researchers are collaborating to determine how CRISPR gene editing can produce more effective chimeric antigen receptor T cells that have the potential to be more durable, less costly and available on demand.